ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Bevacizumab Therapy Effective for Hereditary Hemorrhagic Telangiectasia

by Sue Pondrom • September 17, 2014

  • Tweet
  • Email
Print-Friendly Version

Does bevacizumab delivered as a submucosal and topical intranasal therapy effectively control hereditary hemorrhagic telangiectasia (HHT)-associated epistaxis?

Background: HHT is an autosomal dominant disease with affected patients developing arteriovenous malformations that are prone to bleeding. For moderate and severe cases, epistaxis can be severe and life threatening. HHT patients have been found to have dysfunction in the TGF-β vascular endothelial growth factor (VEGF) signaling cascade.

You Might Also Like

No related posts.

Explore This Issue
March 2012

Study design: Prospective institutional review board-approved study.

Setting: Division of Otolaryngology-Head and Neck Surgery, University of California, San Diego School of Medicine.

Synopsis: For the past five years, the researchers have been treating individuals with moderate to severe epistaxis with a 100-mg intranasal submucosal injection of bevacizumab, a VEGF inhibitor.

For this article, they reported the one-year follow-up of 19 patients treated with 100 mg of intranasal submucosal bevacizumab with or without topical bevacizumab using the epistaxis severity score (ESS) as a barometer for treatment response.

ESS data were recorded for all patients for the first nine months, and for 17 patients in months 10 to 12. Six of the 19 patients received eight additional topical bevacizumab treatments with a 100-mg bevacizumab nasal spray because their bleeding had increased. The mean preinjection ESS for the 19 patients was 8.12, with an ESS nadir of 2.00 reached at two months following submucosal injection. Over the 12 months, the mean ESS steadily increased back to a maximum of 3.6, reached at 11 months.

Bottom line: Bevacizumab is effective in the treatment of HHT epistaxis. For some, topical bevacizumab best treats patients with an ESS below five, and a more advanced disease of five or greater is initially treated with a submucosal injection, followed by topical treatment.

Reference: Karnezis TT, Davidson TM. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy. Laryngoscope. 2012;33(12):495-497.

Filed Under: Literature Reviews, Practice Focus, Rhinology, Rhinology Tagged With: epistaxisIssue: March 2012

You Might Also Like:

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • Some Studies Predict a Shortage of Otolaryngologists. Do the Numbers Support Them?
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Neurogenic Cough Is Often a Diagnosis of Exclusion
    • Complications for When Physicians Change a Maiden Name
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • ENTtoday Editor-In-Chief Search
    • Tympanoplasty Tips: Otology Experts Give Advice on the Procedure
    • How Treatment for Obstructive Sleep Apnea (OSA) Is Evolving to Give Patients a Better Night’s Sleep
    • Vestibular Schwannoma Position Relative to Internal Auditory Canal Helps Predict Postoperative Facial Function
    • Vocal Fold Lipoaugmentation Provides Long-Term Voice Improvements for Glottal Insufficiency

Polls

Do you think there will be a shortage of otolaryngologists in the next five to 10 years?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2022 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.